Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial

• Main Authors: Takashi Nomura (Author), Eriko Sumi (Author), Gyohei Egawa (Author), Saeko Nakajima (Author), Eiko Toichi (Author), Nana Inoue (Author), Mami Shibuya (Author), Natsuko Okamoto (Author), Tsuyoshi Mitsuishi (Author), Ryuji Uozumi (Author), Harue Tada (Author), Takayuki Nakagawa (Author), Nobuhiro Kusuba (Author), Aika Okuno (Author), Chihiro Shimizuhira (Author), Makiko Ishikawa (Author), Shiro Tanaka (Author), Masatoshi Hagiwara (Author), Kenji Kabashima (Author)
• Format: Book
• Published: Elsevier, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Trial design: Human papillomavirus infection causes verruca vulgaris. CDK9 inhibitor FIT039 inhibits DNA virus proliferation in animal models. We conducted a multicenter, single-blind, placebo-controlled, randomized phase I/II clinical trial evaluating the safety and efficacy of FIT039 against verru...